Subsequent Events |
12 Months Ended | |
|---|---|---|
Dec. 31, 2015 | ||
| Subsequent Events [Abstract] | ||
| Subsequent Events |
17. Subsequent Events In February 2016, Checkpoint repaid its NSC Debt of $2.8 million. In January 2016, JMC entered into a product license and supply agreement with a third party to distribute a topical cream to promote wound healing for surgical treatments such as cryosurgery, Mohs surgery and biopsies. Also in January 2016, JMC entered into a distribution agreement with a third party to distribute an emollient for the treatment of Eczema. Both products will be sold under the JMC name. In February 2016, Helocyte paid $1.0 million to enter into a Clinical Trial Agreement with the City of Hope National Medical Center, to support a Phase 2 clinical study of its Triplex vaccine for CMV control in allogeneic stem cell transplant recipients. The Phase 2 study is additionally supported by grants from the National Institutes of Health / National Cancer Institute. Helocyte expects data to emerge from this Phase 2 clinical study in the first half of 2017.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. No definition available.
|